{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:11:30Z","timestamp":1760055090902,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["M\u00e9decine et Maladies Infectieuses"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.medmal.2012.07.018","type":"journal-article","created":{"date-parts":[[2012,8,31]],"date-time":"2012-08-31T21:01:37Z","timestamp":1346446897000},"page":"414-420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacokinetic and dynamic study of levofloxacin and rifampicin in bone and joint infections"],"prefix":"10.1016","volume":"42","author":[{"given":"M.","family":"Guillaume","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Garraffo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bensalem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Bland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Gaillat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-P.","family":"Bru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medmal.2012.07.018_bib0005","unstructured":"Recommendations for clinical practice. Osteo-articular infection therapy according to materials used (prosthesis, implants, osteosynthesis). Med Mal Infect 2009;39(10):745\u201374."},{"issue":"16","key":"10.1016\/j.medmal.2012.07.018_bib0010","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMra040181","article-title":"Prosthetic-joint infections","volume":"351","author":"Zimmerli","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.medmal.2012.07.018_bib0015","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jac\/dkh110","article-title":"Diffusion of levofloxacin into bone and synovial tissues","volume":"53","author":"Rimmele","year":"2004","journal-title":"J Antimicrob Chemother"},{"issue":"19","key":"10.1016\/j.medmal.2012.07.018_bib0020","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/jama.279.19.1537","article-title":"Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group","volume":"279","author":"Zimmerli","year":"1998","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.medmal.2012.07.018_bib0025","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1128\/AAC.37.6.1214","article-title":"Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants","volume":"37","author":"Drancourt","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.medmal.2012.07.018_bib0030","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00003088-199732020-00002","article-title":"The clinical pharmacokinetics of levofloxacin","volume":"32","author":"Fish","year":"1997","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.medmal.2012.07.018_bib0035","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/cir402","article-title":"Outcome and predictors of treatment failure in total hip\/knee prosthetic joint infections due to Staphylococcus aureus","volume":"53","author":"Senneville","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.medmal.2012.07.018_bib0040","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1086\/321854","article-title":"Does the dose matter?","volume":"33","author":"Craig","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.medmal.2012.07.018_bib0045","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1086\/319375","article-title":"What have we learned from pharmacokinetic and pharmacodynamic theories?","volume":"32","author":"Schentag","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.medmal.2012.07.018_bib0050","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1345\/aph.1C199","article-title":"Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models","volume":"37","author":"Schentag","year":"2003","journal-title":"Ann Pharmacother"},{"issue":"10","key":"10.1016\/j.medmal.2012.07.018_bib0055","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1345\/aph.1C419","article-title":"Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials","volume":"37","author":"Schentag","year":"2003","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.medmal.2012.07.018_bib0060","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/jac\/48.2.253","article-title":"Comparative evaluation of oral levofloxacin and parenteral nafcillin in the treatment of experimental methicillin-susceptible Staphylococcus aureus osteomyelitis in rabbits","volume":"48","author":"Shirtliff","year":"2001","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.medmal.2012.07.018_bib0065","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/bmc.1480","article-title":"Development and validation of a fast isocratic liquid chromatography method for the simultaneous determination of norfloxacin, lomefloxacin and ciprofloxacin in human plasma","volume":"25","author":"Sousa","year":"2011","journal-title":"Biomed Chromatogr"},{"issue":"1\u20132","key":"10.1016\/j.medmal.2012.07.018_bib0070","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.chroma.2003.12.041","article-title":"High-performance liquid-chromatographic determination of rifampicin in plasma and tissues","volume":"1031","author":"Calleja","year":"2004","journal-title":"J Chromatogr A"},{"issue":"8","key":"10.1016\/j.medmal.2012.07.018_bib0075","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1128\/AAC.40.8.1775","article-title":"Mechanism of differential activities of ofloxacin enantiomers","volume":"40","author":"Morrissey","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl.\u00a0D","key":"10.1016\/j.medmal.2012.07.018_bib0080","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jac\/26.suppl_D.69","article-title":"Concentrations of ofloxacin in human bone and in cartilage","volume":"26","author":"Meissner","year":"1990","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl.\u00a04","key":"10.1016\/j.medmal.2012.07.018_bib0085","doi-asserted-by":"crossref","first-page":"S270","DOI":"10.1007\/BF01661291","article-title":"Further methodological improvement in antibiotic bone concentration measurements: penetration of ofloxacin into bone and cartilage","volume":"14","author":"Wittmann","year":"1986","journal-title":"Infection"},{"issue":"6","key":"10.1016\/j.medmal.2012.07.018_bib0090","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1179\/joc.2007.19.6.682","article-title":"Penetration of moxifloxacin and levofloxacin into cancellous and cortical bone in patients undergoing total hip arthroplasty","volume":"19","author":"Metallidis","year":"2007","journal-title":"J Chemother"},{"issue":"4","key":"10.1016\/j.medmal.2012.07.018_bib0095","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0924-8579(01)00423-X","article-title":"Tissue and serum concentrations of levofloxacin in orthopaedic patients","volume":"18","author":"von Baum","year":"2001","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.medmal.2012.07.018_bib0100","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/jac\/14.6.647","article-title":"The pharmacokinetics and tissue penetration of ofloxacin","volume":"14","author":"Lockley","year":"1984","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.medmal.2012.07.018_bib0105","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1179\/joc.2007.19.6.688","article-title":"Safety of prolonged high-dose levofloxacin therapy for bone infections","volume":"19","author":"Senneville","year":"2007","journal-title":"J Chemother"},{"issue":"4","key":"10.1016\/j.medmal.2012.07.018_bib0110","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ijantimicag.2008.09.011","article-title":"Treatment of pyogenic (non-tuberculous) spondylodiscitis with tailored high-dose levofloxacin plus rifampicin","volume":"33","author":"Viale","year":"2009","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.medmal.2012.07.018_bib0115","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1128\/AAC.46.5.1503-1509.2002","article-title":"Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus","volume":"46","author":"Vaudaux","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.medmal.2012.07.018_bib0120","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1128\/AAC.00523-06","article-title":"Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus","volume":"50","author":"Murillo","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"9431","key":"10.1016\/j.medmal.2012.07.018_bib0125","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(04)16727-5","article-title":"Osteomyelitis","volume":"364","author":"Lew","year":"2004","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.medmal.2012.07.018_bib0130","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","article-title":"Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients","volume":"37","author":"Forrest","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.medmal.2012.07.018_bib0135","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1086\/314059","article-title":"Clinical pharmacology of the fluoroquinolones: studies in human dynamic\/kinetic models","volume":"31","author":"Schentag","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.medmal.2012.07.018_bib0140","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1128\/AAC.43.3.672","article-title":"Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection","volume":"43","author":"Lacy","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.medmal.2012.07.018_bib0145","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jama.279.2.125","article-title":"Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials","volume":"279","author":"Preston","year":"1998","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.medmal.2012.07.018_bib0150","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1128\/AAC.49.7.2642-2647.2005","article-title":"Antistaphylococcal effect related to the area under the curve\/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones","volume":"49","author":"Firsov","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.medmal.2012.07.018_bib0155","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1086\/319374","article-title":"Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model","volume":"32","author":"Lister","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.medmal.2012.07.018_bib0160","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/jac\/dkl356","article-title":"Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model","volume":"58","author":"Odenholt","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.medmal.2012.07.018_bib0165","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1128\/AAC.42.4.885","article-title":"Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers","volume":"42","author":"Chien","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.medmal.2012.07.018_bib0170","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2165\/00003088-197803020-00002","article-title":"Clinical pharmacokinetics of rifampicin","volume":"3","author":"Acocella","year":"1978","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.medmal.2012.07.018_bib0175","doi-asserted-by":"crossref","first-page":"S428","DOI":"10.1093\/clinids\/5.Supplement_3.S428","article-title":"Pharmacokinetics and metabolism of rifampin in humans","volume":"5","author":"Acocella","year":"1983","journal-title":"Rev Infect Dis"},{"issue":"6","key":"10.1016\/j.medmal.2012.07.018_bib0180","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1469-0691.2007.01691.x","article-title":"Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid","volume":"13","author":"Aboltins","year":"2007","journal-title":"Clin Microbiol Infect"},{"issue":"10\u00a0Pt\u00a02","key":"10.1016\/j.medmal.2012.07.018_bib0185","article-title":"Fluoroquinolone adverse effects and drug interactions","volume":"21","author":"Fish","year":"2001","journal-title":"Pharmacotherapy"}],"container-title":["M\u00e9decine et Maladies Infectieuses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X12002028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X12002028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:11:22Z","timestamp":1759972282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X12002028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0399077X12002028"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2012.07.018","relation":{},"ISSN":["0399-077X"],"issn-type":[{"type":"print","value":"0399-077X"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic and dynamic study of levofloxacin and rifampicin in bone and joint infections","name":"articletitle","label":"Article Title"},{"value":"M\u00e9decine et Maladies Infectieuses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2012.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}